DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial

Information source: Third Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Induced Abortion; Anesthesia

Intervention: pentazocine (Drug); propofol (Drug); Etomidate (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Third Affiliated Hospital of Zhengzhou University

Summary

To explore the feasibility of different doses of etomidate admixed with propofol in induced abortion: a randomized, double blind controlled trial.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Heart rate

Blood pressure

Pulse oxygen saturation

Secondary outcome:

Efficacy of anesthesia

Dose of propofol or mixture of propofol and etomidate

Use of specific medications

Aldrete score

Verbal rating scales of uterine contraction

Satisfaction degree of the patient, the surgeon and the anesthetist

Eligibility

Minimum age: 20 Years. Maximum age: 35 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Aged between 20 and 35 years

- American Society of Anesthesiology (ASA) Physical Status: Ⅰ or Ⅱ

- Singleton pregnancy and the gestational period is 6 to 8 weeks

- Expected operation duration is within 60 minutes

- The body weight should be within 15% around the standard weight

- Signed informed consent form

Exclusion Criteria:

- Serious cardiac, cerebral, liver, kidney, lung, endocrine disease

- Upper respiratory infections within 4 weeks

- Long use of hormone or history of adrenal suppression

- History of use of glucocorticoids, aprotinin or immunosuppressant

- Manifestation of immunodeficiency

- History of use of sedatives or opiates

- Needs of Neuromuscular blocker (except intubation)

- Allergy to trial drug or other contraindication

- Pregnant or breast-feeding women

- Attended other trial past 30 days

Locations and Contacts

Additional Information

Starting date: September 2014
Last updated: August 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017